Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.91 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576032 | 1.00 | HTR1A (0.91) | HTR1ASLC6A4SLC6A2SLC6A3ADRA1D | |
| SCHEMBL6575469 | 0.95 | HTR1A (1.00) | HTR1ASLC6A4SLC6A2SLC6A3ADRA1D | |
| SCHEMBL6575465 | 0.95 | HTR1A (1.00) | HTR1ASLC6A4SLC6A2SLC6A3ADRA1D | |
| SCHEMBL6573474 | 0.84 | HTR1A (0.79) | HTR1ASLC6A4SLC6A2SLC6A3ADRA1D | |
| SCHEMBL6574125 | 0.83 | HTR1A (0.92) | HTR1ASLC6A4 | |
| SCHEMBL6574130 | 0.83 | HTR1A (0.92) | HTR1ASLC6A4 | |
| SCHEMBL6574196 | 0.81 | HTR1A (0.73) | HTR1ASLC6A4 | |
| SCHEMBL6574201 | 0.81 | HTR1A (0.73) | HTR1ASLC6A4 | |
| SCHEMBL6575890 | 0.78 | HTR1A (1.00) | HTR1ASLC6A4 | |
| SCHEMBL6577432 | 0.78 | HTR1A (1.00) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | claimed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | HTR1A 1/4885SLC6A4 90/4885SLC6A2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.